New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer - Top-Institutions - MDSpire

New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer

A new study from researchers at Fox Chase Cancer Center and collaborators across multiple institutions has identified a hidden subset of lung cancers that behave more like aggressive neuroendocrine tumors than traditional non-small cell lung cancer (NSCLC).

  • By

  • June 3, 2026

  • 4 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Fox Chase Cancer Center
    Fox Chase Cancer Center

    Philadelphia, PA

    Key Differentiators

    • Oncology

  • #2

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, FL

    Key Differentiators

    • Oncology

  • #3

    The Ohio State University Wexner Medical Center
    The Ohio State University Wexner Medical Center

    Columbus, OH

    Key Differentiators

    • Oncology

  • #4

    Georgetown University
    Georgetown University

    Washington, DC

    Key Differentiators

    • Oncology

  • #5

    Montefiore Medical Center
    Montefiore Medical Center

    Bronx, NY

    Key Differentiators

    • Oncology

Original Source(s)

New Study Identifies Hidden Aggressive and Potentially Targetable Neuroendocrine-Like Subtype of Lung Cancer

  • by

  • June 3, 2026

Related Content

Renowned medical oncologist shares key takeaways from ASCO 2026

Farshid Dayyani, MD, PhD shared his key takeaways on emerging developments in gastrointestinal oncology at ASCO 2026.

  • June 25, 2026

  • 1 min
ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

  • June 24, 2026

  • 1 min